<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8"><meta name="viewport" content="width=device-width, initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes">
    <title>üéß Rheumatology Study Guide ‚Äî Audio Edition</title>
    <style>
        :root { --primary: #0284c7; --primary-light: #38bdf8; --accent: #e07b53; --bg: #1a1a2e; --card-bg: #16213e; --text: #e8e8e8; --text-muted: #a0a0a0; --border: #2d3a4f; }
        * { box-sizing: border-box; margin: 0; padding: 0; }
        body { font-family: -apple-system, sans-serif; background: var(--bg); color: var(--text); line-height: 1.8; padding: 20px; padding-bottom: 200px; font-size: 18px; }
        .header { text-align: center; padding: 30px 20px; background: linear-gradient(135deg, var(--primary), var(--primary-light)); border-radius: 16px; margin-bottom: 20px; }
        .header h1 { font-size: 1.5rem; margin-bottom: 8px; }
        .audio-controls { position: fixed; bottom: 0; left: 0; right: 0; background: rgba(22,33,62,0.98); padding: 15px 20px; padding-bottom: max(15px, env(safe-area-inset-bottom)); border-top: 1px solid var(--border); z-index: 1000; }
        .controls-row { display: flex; align-items: center; justify-content: center; gap: 15px; margin-bottom: 10px; }
        .control-btn { background: var(--primary); border: none; color: white; width: 50px; height: 50px; border-radius: 50%; font-size: 1.3rem; cursor: pointer; display: flex; align-items: center; justify-content: center; }
        .control-btn.play-btn { width: 65px; height: 65px; font-size: 1.6rem; background: var(--accent); }
        .progress-section { display: flex; align-items: center; gap: 10px; font-size: 0.8rem; color: var(--text-muted); }
        .progress-bar { flex: 1; height: 6px; background: var(--border); border-radius: 3px; cursor: pointer; }
        .progress-fill { height: 100%; background: var(--accent); width: 0%; }
        .current-topic { text-align: center; font-size: 0.85rem; color: var(--accent); margin-top: 8px; }
        .settings-row { display: flex; justify-content: center; gap: 20px; margin-top: 10px; }
        .speed-control select, .pause-control select { background: var(--card-bg); color: var(--text); border: 1px solid var(--border); padding: 6px 10px; border-radius: 8px; }
        .section { background: var(--card-bg); border-radius: 12px; margin-bottom: 20px; }
        .section-header { background: var(--primary); padding: 15px 20px; font-size: 1.1rem; font-weight: 600; display: flex; justify-content: space-between; }
        .section-content { padding: 20px; }
        .topic { margin-bottom: 25px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
        .topic:last-child { border-bottom: none; }
        .topic-title { font-size: 1.1rem; font-weight: 600; color: var(--accent); margin-bottom: 15px; }
        .content-block { margin-bottom: 15px; padding: 15px; background: rgba(255,255,255,0.03); border-radius: 8px; border-left: 3px solid var(--primary); }
        .content-block.high-yield { border-left-color: #ef4444; background: rgba(239, 68, 68, 0.1); }
        .block-label { font-size: 0.75rem; text-transform: uppercase; color: var(--text-muted); margin-bottom: 8px; }
        .current { background: rgba(2, 132, 199, 0.3); border-radius: 3px; }
        .voice-selector { margin: 15px 0; padding: 15px; background: var(--card-bg); border-radius: 12px; }
        .voice-selector select { width: 100%; padding: 10px; background: var(--bg); color: var(--text); border: 1px solid var(--border); border-radius: 8px; }
        .toc { background: var(--card-bg); border-radius: 12px; padding: 20px; margin-bottom: 20px; }
        .toc-item { padding: 10px 15px; margin: 5px 0; background: rgba(255,255,255,0.03); border-radius: 8px; cursor: pointer; display: flex; justify-content: space-between; }
        .toc-item.active { background: var(--primary); }
    </style>
</head>
<body>
<div class="header"><h1>ü¶¥ Rheumatology Study Guide</h1><p>Audio Edition ‚Ä¢ ABIM Board Review ‚Ä¢ 8% of Exam</p><p style="font-size:0.8rem; opacity:0.7; margin-top:8px;">v1.0 BUILD #8</p></div>
<div class="voice-selector"><label>üéôÔ∏è Voice:</label><select id="voiceSelect"></select></div>
<div class="toc"><h2>üìã Chapters</h2>
    <div class="toc-item" data-section="0"><span>1. Rheumatoid Arthritis</span><span>~6 min</span></div>
    <div class="toc-item" data-section="1"><span>2. SLE</span><span>~7 min</span></div>
    <div class="toc-item" data-section="2"><span>3. Vasculitis</span><span>~6 min</span></div>
    <div class="toc-item" data-section="3"><span>4. Crystal Arthropathies</span><span>~6 min</span></div>
    <div class="toc-item" data-section="4"><span>5. Spondyloarthropathies</span><span>~5 min</span></div>
    <div class="toc-item" data-section="5"><span>6. Myopathies & Scleroderma</span><span>~5 min</span></div>
</div>
<div id="audioContent">
<div class="section" data-section="0">
    <div class="section-header"><span>1. Rheumatoid Arthritis</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Diagnosis</div>
            <div class="content-block"><div class="block-label">Clinical Features</div>
                <p class="speakable">RA presents with symmetric inflammatory polyarthritis affecting small joints of hands and feet.</p>
                <p class="speakable">Classic involvement is MCP and PIP joints with sparing of DIP joints. Morning stiffness lasting more than 1 hour is typical.</p>
                <p class="speakable">Extra-articular manifestations include rheumatoid nodules, interstitial lung disease, Felty syndrome, and vasculitis.</p>
            </div>
            <div class="content-block high-yield"><div class="block-label">Serology</div>
                <p class="speakable">Rheumatoid factor is sensitive but not specific. It is positive in 70 to 80 percent of RA patients.</p>
                <p class="speakable">Anti-CCP antibodies are more specific and predict erosive disease. They can be positive before clinical symptoms.</p>
                <p class="speakable">Seronegative RA with negative RF and anti-CCP occurs in about 20 percent of cases.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Treatment</div>
            <div class="content-block high-yield"><div class="block-label">DMARD Therapy</div>
                <p class="speakable">Methotrexate is first-line DMARD. Start early to prevent joint destruction.</p>
                <p class="speakable">Give folic acid supplementation to reduce side effects. Monitor CBC and LFTs.</p>
                <p class="speakable">If inadequate response, add or switch to biologic DMARD: TNF inhibitors, abatacept, tocilizumab, or rituximab.</p>
                <p class="speakable">JAK inhibitors tofacitinib and baricitinib are oral alternatives to biologics.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="1">
    <div class="section-header"><span>2. SLE</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Diagnosis</div>
            <div class="content-block high-yield"><div class="block-label">ACR/EULAR Criteria</div>
                <p class="speakable">SLE diagnosis requires positive ANA plus clinical and immunologic criteria with total score 10 or more.</p>
                <p class="speakable">Clinical domains include constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, and renal.</p>
                <p class="speakable">Key antibodies are anti-dsDNA which correlates with disease activity and lupus nephritis, and anti-Smith which is highly specific.</p>
                <p class="speakable">Low complements C3 and C4 suggest active disease.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Key Manifestations</div>
            <div class="content-block"><div class="block-label">Lupus Nephritis</div>
                <p class="speakable">Renal involvement occurs in about 50 percent of SLE patients and is a major cause of morbidity.</p>
                <p class="speakable">Class 3 and 4 proliferative nephritis require aggressive immunosuppression with mycophenolate or cyclophosphamide.</p>
                <p class="speakable">All lupus patients should receive hydroxychloroquine unless contraindicated.</p>
            </div>
            <div class="content-block high-yield"><div class="block-label">Antiphospholipid Syndrome</div>
                <p class="speakable">APS causes arterial and venous thrombosis plus pregnancy morbidity.</p>
                <p class="speakable">Diagnose with lupus anticoagulant, anticardiolipin antibodies, or anti-beta-2-glycoprotein antibodies positive on 2 occasions 12 weeks apart.</p>
                <p class="speakable">Treatment is anticoagulation. Warfarin is preferred for arterial events. DOACS are acceptable for venous events.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="2">
    <div class="section-header"><span>3. Vasculitis</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Large Vessel Vasculitis</div>
            <div class="content-block high-yield"><div class="block-label">Giant Cell Arteritis</div>
                <p class="speakable">GCA affects patients over 50, typically with new headache, scalp tenderness, jaw claudication, and visual symptoms.</p>
                <p class="speakable">ESR and CRP are markedly elevated. Temporal artery biopsy shows granulomatous inflammation.</p>
                <p class="speakable">Start high-dose steroids immediately if clinical suspicion is high. Do not wait for biopsy. Vision loss can be permanent.</p>
                <p class="speakable">Tocilizumab is steroid-sparing and reduces relapse risk.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">ANCA-Associated Vasculitis</div>
            <div class="content-block high-yield"><div class="block-label">GPA, MPA, EGPA</div>
                <p class="speakable">GPA, formerly Wegener's, affects upper airways, lungs, and kidneys. PR3-ANCA, or c-ANCA, is positive in 90 percent.</p>
                <p class="speakable">MPA causes pulmonary-renal syndrome without upper airway involvement. MPO-ANCA, or p-ANCA, is typically positive.</p>
                <p class="speakable">EGPA, formerly Churg-Strauss, presents with asthma, eosinophilia, and vasculitis. MPO-ANCA positive in about 40 percent.</p>
                <p class="speakable">Treatment is rituximab or cyclophosphamide plus steroids for induction. Rituximab or azathioprine for maintenance.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="3">
    <div class="section-header"><span>4. Crystal Arthropathies</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Gout</div>
            <div class="content-block high-yield"><div class="block-label">Diagnosis and Treatment</div>
                <p class="speakable">Acute gout presents with rapid onset of severe monoarticular arthritis, classically the first MTP joint or podagra.</p>
                <p class="speakable">Synovial fluid shows negatively birefringent needle-shaped crystals.</p>
                <p class="speakable">Acute treatment options are NSAIDs, colchicine, or steroids. Choose based on comorbidities.</p>
                <p class="speakable">Do not start or stop urate-lowering therapy during an acute flare. It can prolong or worsen the attack.</p>
                <p class="speakable">Urate-lowering therapy with allopurinol or febuxostat is indicated for frequent attacks, tophi, or uric acid stones. Target uric acid less than 6.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Pseudogout</div>
            <div class="content-block"><div class="block-label">CPPD Disease</div>
                <p class="speakable">Calcium pyrophosphate deposition disease presents similarly to gout but often affects the knee or wrist.</p>
                <p class="speakable">Synovial fluid shows positively birefringent rhomboid-shaped crystals.</p>
                <p class="speakable">X-ray shows chondrocalcinosis, which is calcification of cartilage.</p>
                <p class="speakable">Associated with hemochromatosis, hyperparathyroidism, and hypomagnesemia.</p>
                <p class="speakable">Treatment of acute attacks is similar to gout. No urate-lowering equivalent exists for CPPD.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="4">
    <div class="section-header"><span>5. Spondyloarthropathies</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Ankylosing Spondylitis</div>
            <div class="content-block high-yield"><div class="block-label">Key Features</div>
                <p class="speakable">AS presents with inflammatory back pain in young adults. Pain is worse at rest, improves with exercise, and causes morning stiffness.</p>
                <p class="speakable">HLA-B27 is positive in over 90 percent of cases.</p>
                <p class="speakable">X-ray findings include sacroiliitis and syndesmophytes leading to bamboo spine in advanced disease.</p>
                <p class="speakable">MRI is more sensitive for early sacroiliitis before X-ray changes.</p>
                <p class="speakable">Treatment is NSAIDs first, then TNF inhibitors or IL-17 inhibitors like secukinumab.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Reactive Arthritis</div>
            <div class="content-block"><div class="block-label">Classic Triad</div>
                <p class="speakable">Reactive arthritis presents with arthritis, urethritis, and conjunctivitis. Often occurs after GI or GU infection.</p>
                <p class="speakable">Common triggers are Chlamydia, Salmonella, Shigella, Campylobacter, and Yersinia.</p>
                <p class="speakable">Treatment is NSAIDs. Prolonged antibiotics may be used for Chlamydia-triggered cases.</p>
            </div>
        </div>
    </div>
</div>
<div class="section" data-section="5">
    <div class="section-header"><span>6. Myopathies & Scleroderma</span><span>‚ñ∂Ô∏è</span></div>
    <div class="section-content">
        <div class="topic"><div class="topic-title">Inflammatory Myopathies</div>
            <div class="content-block high-yield"><div class="block-label">DM vs PM</div>
                <p class="speakable">Both dermatomyositis and polymyositis present with proximal muscle weakness and elevated CK.</p>
                <p class="speakable">Dermatomyositis has characteristic skin findings: heliotrope rash around eyes, Gottron papules over knuckles, shawl sign, and V-sign.</p>
                <p class="speakable">Dermatomyositis is associated with underlying malignancy. Screen for cancer especially in adults.</p>
                <p class="speakable">Anti-Jo-1 antibody is associated with interstitial lung disease, mechanics hands, and arthritis.</p>
                <p class="speakable">Treatment is high-dose steroids plus steroid-sparing agents like methotrexate or azathioprine.</p>
            </div>
        </div>
        <div class="topic"><div class="topic-title">Systemic Sclerosis</div>
            <div class="content-block"><div class="block-label">Limited vs Diffuse</div>
                <p class="speakable">Limited cutaneous SSc, formerly CREST, affects skin distal to elbows and knees. Associated with pulmonary hypertension and anti-centromere antibody.</p>
                <p class="speakable">Diffuse cutaneous SSc has widespread skin involvement and higher risk of renal crisis and interstitial lung disease. Associated with anti-Scl-70 antibody.</p>
                <p class="speakable">Scleroderma renal crisis presents with hypertensive emergency and AKI. Treat with ACE inhibitors.</p>
            </div>
        </div>
    </div>
</div>
</div>
<div class="audio-controls">
    <div class="controls-row"><button class="control-btn" onclick="skipBackward()">‚è™</button><button class="control-btn play-btn" id="playPauseBtn" onclick="togglePlayPause()">‚ñ∂Ô∏è</button><button class="control-btn" onclick="skipForward()">‚è©</button><button class="control-btn" onclick="stopReading()">‚èπÔ∏è</button></div>
    <div class="progress-section"><span id="currentTime">0:00</span><div class="progress-bar" onclick="seekTo(event)"><div class="progress-fill" id="progressFill"></div></div><span id="totalTime">0:00</span></div>
    <div class="current-topic" id="currentTopic">Ready to play</div>
    <div class="settings-row"><div class="speed-control"><label>Speed:</label><select id="speedSelect" onchange="updateSpeed()"><option value="0.75">0.75√ó</option><option value="1" selected>1√ó</option><option value="1.5">1.5√ó</option><option value="2">2√ó</option></select></div><div class="pause-control"><label>Pauses:</label><select id="pauseSelect" onchange="updatePauses()"><option value="short">Short</option><option value="medium" selected>Medium</option><option value="long">Long</option></select></div></div>
</div>
<script>
let isPlaying=false,currentSentenceIndex=0,sentences=[],speechRate=1,englishVoices=[],pauseSettings={sentence:400,paragraph:800,section:1500};
document.addEventListener('DOMContentLoaded',()=>{loadVoices();buildSentenceList();setupTOC();const s=localStorage.getItem('rheum_audio_pos');if(s)currentSentenceIndex=parseInt(s)||0;});
function loadVoices(){const sel=document.getElementById('voiceSelect');function pop(){const all=speechSynthesis.getVoices();englishVoices=all.filter(v=>v.lang.startsWith('en-'));if(!englishVoices.length){setTimeout(pop,100);return;}sel.innerHTML='';englishVoices.forEach((v,i)=>{const o=document.createElement('option');o.value=i;o.textContent=`${v.localService?'‚≠ê ':''}${v.name}`;sel.appendChild(o);});}pop();speechSynthesis.onvoiceschanged=pop;}
function buildSentenceList(){sentences=[];document.querySelectorAll('.speakable').forEach((el,i,arr)=>{const sec=el.closest('.section'),top=el.closest('.topic');sentences.push({text:el.textContent.trim(),element:el,section:sec?parseInt(sec.dataset.section):0,topic:top?.querySelector('.topic-title')?.textContent||'',isNewBlock:i===0||el.closest('.content-block')!==arr[i-1]?.closest('.content-block'),isNewSection:i===0||(sec?.dataset.section!==arr[i-1]?.closest('.section')?.dataset.section)});});updateProgress();}
function setupTOC(){document.querySelectorAll('.toc-item').forEach(item=>{item.addEventListener('click',()=>jumpToSection(parseInt(item.dataset.section)));});}
function jumpToSection(idx){const i=sentences.findIndex(s=>s.section===idx);if(i!==-1){currentSentenceIndex=i;if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}}
function togglePlayPause(){isPlaying?pauseReading():startReading();}
function startReading(){isPlaying=true;document.getElementById('playPauseBtn').textContent='‚è∏Ô∏è';speakCurrentSentence();}
function pauseReading(){isPlaying=false;speechSynthesis.cancel();document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';localStorage.setItem('rheum_audio_pos',currentSentenceIndex);}
function stopReading(){isPlaying=false;speechSynthesis.cancel();currentSentenceIndex=0;document.getElementById('playPauseBtn').textContent='‚ñ∂Ô∏è';updateProgress();localStorage.removeItem('rheum_audio_pos');}
function speakCurrentSentence(){if(!isPlaying||currentSentenceIndex>=sentences.length){if(currentSentenceIndex>=sentences.length)stopReading();return;}const s=sentences[currentSentenceIndex],u=new SpeechSynthesisUtterance(s.text),vi=parseInt(document.getElementById('voiceSelect').value)||0;if(englishVoices[vi])u.voice=englishVoices[vi];u.lang='en-US';u.rate=speechRate;document.querySelectorAll('.current').forEach(el=>el.classList.remove('current'));s.element.classList.add('current');s.element.scrollIntoView({behavior:'smooth',block:'center'});document.getElementById('currentTopic').textContent=s.topic;updateProgress();u.onend=()=>{currentSentenceIndex++;if(currentSentenceIndex<sentences.length){let p=pauseSettings.sentence;if(sentences[currentSentenceIndex].isNewSection)p=pauseSettings.section;else if(sentences[currentSentenceIndex].isNewBlock)p=pauseSettings.paragraph;setTimeout(()=>{if(isPlaying)speakCurrentSentence();},p);}else stopReading();};speechSynthesis.speak(u);}
function updateProgress(){const pct=sentences.length?(currentSentenceIndex/sentences.length)*100:0;document.getElementById('progressFill').style.width=pct+'%';const avg=3/speechRate;document.getElementById('currentTime').textContent=Math.floor(currentSentenceIndex*avg/60)+':'+(Math.floor(currentSentenceIndex*avg)%60).toString().padStart(2,'0');document.getElementById('totalTime').textContent=Math.floor(sentences.length*avg/60)+':'+(Math.floor(sentences.length*avg)%60).toString().padStart(2,'0');}
function seekTo(e){currentSentenceIndex=Math.floor((e.offsetX/e.currentTarget.offsetWidth)*sentences.length);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipForward(){currentSentenceIndex=Math.min(currentSentenceIndex+10,sentences.length-1);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function skipBackward(){currentSentenceIndex=Math.max(currentSentenceIndex-10,0);if(isPlaying){speechSynthesis.cancel();speakCurrentSentence();}updateProgress();}
function updateSpeed(){speechRate=parseFloat(document.getElementById('speedSelect').value);updateProgress();}
function updatePauses(){const s=document.getElementById('pauseSelect').value;pauseSettings=s==='short'?{sentence:200,paragraph:400,section:800}:s==='long'?{sentence:600,paragraph:1200,section:2000}:{sentence:400,paragraph:800,section:1500};}
</script>
</body>
</html>
